Sexually Transmitted Diseases

Adolescent STIs are rising. Diane Straub, MD, MPH, stressed confidential care, routine screening, and balancing parental involvement at AAP 2025.

Universal EHR-based decision support eliminated racial disparities in adolescent chlamydia and gonorrhea testing in pediatric EDs.

FDA accepts priority review of gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients ≥12 years.

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated.

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

Lea Widdice, MD, details her recent presentation at PAS 2025 on OTC STI testing within pediatrics.

Early HPV vaccination at age 9 boosts completion rates, reduces disparities, and enhances cancer prevention effort, according to a recent study from Nemours Children's Health.

HPV vaccination in Brazil led to significant reductions in genital warts and cervical precancer hospitalizations, especially among those under 20 years of age.

In this last episode, our panel discusses this patient population and the challenges around keeping them in the continuum of care.

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

Expert discussion of several topics including diagnosis, clinical management in older adults, multidrug resistance, and long-acting injectables and PrEP.

The 2-drug, fixed-dose combination tablet contains darunavir, an HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor that serves as a PK enhancer or “booster.”

Following evidence from recent studies, the CDC has recommended the use of doxycycline postexposure prophylaxis in sexual health among certain populations.

According to the report authors, girls were more likely to receive 1 or more HPV vaccine doses compared to boys (42.9% vs 34.6%).

A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.

The low-dose, coformulated regimen was well tolerated, and overall data supports its use in children with HIV aged 2 years and older weighing between 30.86 lbs (14 kg) and 55.11 lbs (25 kg).

The CDC's take on the importance of HIV awareness and testing among our youth.

April 10, 2024 is National Youth HIV & AIDS Awareness Day.

The treatment is approved for adolescents aged 12 years and older.

Natasha Hoyte, MPH, CPNP-PC, explains how important PrEP and PEP in school health programs can be for youth, and the crucial role awareness plays.

Administration of the HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) to the indicated population can be done via 25 mg oral tablets or new 2.5 mg oral tablets, developed to help administration and weight-adjusted dosing for children.

Discover effective counseling techniques and overcome barriers to empower adolescents in making informed decisions about contraception, fostering trust, confidentiality, and autonomy in reproductive health care.

Deborah Persaud, MD, details results from her study that aimed to reduce HIV reservoirs in neonates with very early antiretroviral therapy.

Investigators recently noted that despite a decrease in adolescent hospital visits during the height of the pandemic, there was an increase in sexually transmitted infections (STIs) in this population group.